Indirect Estimation of the Prevalence of Type 2 Diabetes Mellitus in the Sub-population of Tehran: Using Non-laboratory Risk-score Models in Iran

Overview

Journal BMC Public Health

Publisher Biomed Central

Specialty Public Health

Date 2024 Oct 12

PMID 39395938

Authors

Yosra Azizpour

Samaneh Asgari

Mehdi Yaseri

Akbar Fotouhi

Samaneh Akbarpour

Affiliations

Soon will be listed here.

Abstract

Background: The prevalence of type 2 diabetes mellitus (T2DM) in the population covered by the Tehran University of Medical Sciences is unclear but crucial for healthcare programs. This study aims to validate four non-laboratory risk-score models, the American Diabetes Association (ADA) Risk Score, Australian Type 2 Diabetes Risk Assessment Tool (AUSDRISK), Finnish Diabetes Risk Score (FINDRISC), and TOPICS Diabetes Screening Score, for identifying undiagnosed diabetes and indirectly estimate the prevalence of T2DM in a subset of the Tehranian population using the selected model.

Methods: This research consisted of two main parts. In the first part, non-laboratory risk-score models to identify undiagnosed T2DM were validated using Iranian data from STEPs 2016 survey. The model performance was evaluated through the Area Under the Curve (AUC) and calibration via the observed-to-expected (O/E) ratio. Additional independent data from STEPs 2011 survey in Iran were utilized to test the model results by comparing indirect prevalence estimates with observed estimates. In the second part, the prevalence of T2DM was estimated indirectly by applying the selected model to a representative random sample from a Tehranian population telephone survey conducted in 2023.

Results: Among the different models used, AUSDRISK showed the best performance in both discrimination (AUC (95% confidence interval (CI)): 0.80 (0.78, 0.81)) and calibration (O/E ratio = 1.01). After updating the original model, there was no change in the AUC value or calibration. Additionally, our findings indicate that the indirect estimates are nearly identical to the observed values in STEPs 2011 survey. In the second part of the study, by applying the recalibrated model to a subsample, the indirect prevalence of undiagnosed diabetes and T2DM (95% CI) were estimated at 4.18% (3.87, 4.49) and 11.1% (9.34, 13.1), respectively.

Conclusion: Given the strong performance of the model, it appears that indirect method can provide a cost-effective and simple approach to assess disease prevalence and intervention effectiveness.

References

Esteghamati A, Etemad K, Koohpayehzadeh J, Abbasi M, Meysamie A, Noshad S . Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005-2011. Diabetes Res Clin Pract. 2014; 103(2):319-27. DOI: 10.1016/j.diabres.2013.12.034. View

Park S, Gillespie C, Baumgardner J, Yang Q, Valderrama A, Fang J . Modeled state-level estimates of hypertension prevalence and undiagnosed hypertension among US adults during 2013-2015. J Clin Hypertens (Greenwich). 2018; 20(10):1395-1410. PMC: 8031025. DOI: 10.1111/jch.13388. View

Oh K, Kim Y, Kweon S, Kim S, Yun S, Park S . Korea National Health and Nutrition Examination Survey, 20th anniversary: accomplishments and future directions. Epidemiol Health. 2021; 43:e2021025. PMC: 8289475. DOI: 10.4178/epih.e2021025. View

Christodoulou E, Ma J, Collins G, Steyerberg E, Verbakel J, Van Calster B . A systematic review shows no performance benefit of machine learning over logistic regression for clinical prediction models. J Clin Epidemiol. 2019; 110:12-22. DOI: 10.1016/j.jclinepi.2019.02.004. View

Kroll M, Phalkey R, Kraas F . Challenges to the surveillance of non-communicable diseases--a review of selected approaches. BMC Public Health. 2015; 15:1243. PMC: 4682212. DOI: 10.1186/s12889-015-2570-z. View

Barr M, Dillon A, Kassis M, Steel D . Telephone surveys provide reliable information on risk behaviours and health status of Aboriginal and Torres Strait Islander people. Aust N Z J Public Health. 2013; 37(1):91-2. DOI: 10.1111/1753-6405.12017. View

Vergouwe Y, Steyerberg E, Eijkemans M, Habbema J . Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J Clin Epidemiol. 2005; 58(5):475-83. DOI: 10.1016/j.jclinepi.2004.06.017. View

Tabatabaei-Malazy O, Moghaddam S, Rezaei N, Sheidaei A, Hajipour M, Mahmoudi N . A nationwide study of metabolic syndrome prevalence in Iran; a comparative analysis of six definitions. PLoS One. 2021; 16(3):e0241926. PMC: 7928520. DOI: 10.1371/journal.pone.0241926. View

Kolahi A, Moghisi A, Soleiman Ekhtiari Y . Socio-demographic determinants of obesity indexes in Iran: findings from a nationwide STEPS survey. Health Promot Perspect. 2018; 8(3):187-194. PMC: 6064748. DOI: 10.15171/hpp.2018.25. View

10.

Lindstrom J, Tuomilehto J . The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care. 2003; 26(3):725-31. DOI: 10.2337/diacare.26.3.725. View

11.

Ahn C, Yoon J, Hahn S, Moon M, Park K, Cho Y . Evaluation of Non-Laboratory and Laboratory Prediction Models for Current and Future Diabetes Mellitus: A Cross-Sectional and Retrospective Cohort Study. PLoS One. 2016; 11(5):e0156155. PMC: 4877115. DOI: 10.1371/journal.pone.0156155. View

12.

Lotfaliany M, Hadaegh F, Asgari S, Mansournia M, Azizi F, Oldenburg B . Non-invasive Risk Prediction Models in Identifying Undiagnosed Type 2 Diabetes or Predicting Future Incident Cases in the Iranian Population. Arch Iran Med. 2019; 22(3):116-124. View

13.

Mahmoodzadeh S, Jahani Y, Najafipour H, Sanjari M, Shadkam-Farokhi M, Shahesmaeili A . External Validation of Finnish Diabetes Risk Score and Australian Diabetes Risk Assessment Tool Prediction Models to Identify People with Undiagnosed Type 2 Diabetes: A Cross-sectional Study in Iran. Int J Endocrinol Metab. 2023; 20(4):e127114. PMC: 9871969. DOI: 10.5812/ijem-127114. View

14.

Azadnajafabad S, Ahmadi N, Rezaei N, Rashidi M, Moghaddam S, Mohammadi E . Evaluation of the diabetes care cascade and compliance with WHO global coverage targets in Iran based on STEPS survey 2021. Sci Rep. 2023; 13(1):13528. PMC: 10439917. DOI: 10.1038/s41598-023-39433-7. View

15.

Asgari S, Lotfaliany M, Fahimfar N, Hadaegh F, Azizi F, Khalili D . The external validity and performance of the no-laboratory American Diabetes Association screening tool for identifying undiagnosed type 2 diabetes among the Iranian population. Prim Care Diabetes. 2020; 14(6):672-677. DOI: 10.1016/j.pcd.2020.04.001. View

16.

Ogurtsova K, Guariguata L, Barengo N, Ruiz P, Sacre J, Karuranga S . IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract. 2021; 183:109118. DOI: 10.1016/j.diabres.2021.109118. View

17.

Binuya M, Engelhardt E, Schats W, Schmidt M, Steyerberg E . Methodological guidance for the evaluation and updating of clinical prediction models: a systematic review. BMC Med Res Methodol. 2022; 22(1):316. PMC: 9742671. DOI: 10.1186/s12874-022-01801-8. View

18.

Bang H, Edwards A, Bomback A, Ballantyne C, Brillon D, Callahan M . Development and validation of a patient self-assessment score for diabetes risk. Ann Intern Med. 2009; 151(11):775-83. PMC: 3633111. DOI: 10.7326/0003-4819-151-11-200912010-00005. View

19.

Saidi O, Oflaherty M, Ben Mansour N, Aissi W, Lassoued O, Capewell S . Forecasting Tunisian type 2 diabetes prevalence to 2027: validation of a simple model. BMC Public Health. 2015; 15:104. PMC: 4348374. DOI: 10.1186/s12889-015-1416-z. View

20.

Djalalinia S, Azadnajafabad S, Ghasemi E, Yoosefi M, Rezaei N, Farzi Y . Protocol Design for Surveillance of Risk Factors of Non-communicable Diseases During the COVID-19 Pandemic: An Experience from Iran STEPS Survey 2021. Arch Iran Med. 2023; 25(9):634-646. PMC: 10685773. DOI: 10.34172/aim.2022.99. View